首页|金水宝治疗早期糖尿病肾病的系统评价

金水宝治疗早期糖尿病肾病的系统评价

扫码查看
目的 系统评价金水宝治疗早期糖尿病肾病(DN)的有效性及安全性.方法 在PubMed、Cochrane Librar-y、Web of Science和Embase等外文数据库,及中国知网、万方和维普等中文数据库中进行全面的检索,检索的时限为建库到 2023 年 7 月,根据Cochrane评估手册5.3.3 的评估标准评估受试者的方法学质量.采用RevMan 5.4 软件对相关数据进行分析.结果 本研究纳入文献20 篇,共纳入1514 例研究对象,观察组758 例,对照组756 例.Me-ta分析结果显示:观察组总有效率高于对照组[RR= 2.53,95%CI(1.77,3.62),P<0.00001];观察组UAER高于对照组[MD=-34.67,95%CI(-41.76,-27.58),P<0.00001];观察组血SCr低于对照组[MD=-13.01,95%CI(-15.61,-10.41),P<0.00001];观察组 BUN水平低于对照组[MD=-1.38,95%CI(-2.06,-0.69),P<0.00001];观察组HbA1C水平低于于对照组[MD=-0.63,95%CI(-1.14,-0.13),P<0.00001].结论 现有的临床证据表明,金水宝联合西药治疗早期糖尿病肾病较单纯西药治疗更有效,值得临床推广应用,但还需更多的多中心大样本随机对照试验(RCTs)研究进行验证.
Systematic Evaluation of Jinshuibao in Treatment of Early Diabetic Nephropathy
Objective To systematically evaluate the effectiveness and safety of Jinshuibao in the treatment of early diabetic nephropathy.Method Comprehensive searches were conducted in foreign language databases such as PubMed,Cochrane Library,Web of Science and Em-base,and Chinese databases such as CNKI,Wanfang and CQVIP,with a timeframe from the construction of the database to July,2023.The methodological quality of the subjects was as-sessed according to the assessment criteria of the Cochrane Assessment Handbook 5.3.3.Rev-Man 5.4 software was used to analyze relevant data.Results This study included 20 articles in the literature,including a total of 1,514 patients(758 in the observation group and 756 in the control group).Meta analysis results show that the total efficiency of the observation group is higher than that of the control group[RR =2.53,95%CI(1.77,3.62),P<0.00001];UAER in the ob-servation group is higher than that of the control group[MD =-34.67,95%CI(-41.76,27.58),P<0.00001];the blood SCr in the observation group is lower than that of the control group[MD=-13.01,95%CI(-15.61,-10.41),P<0.00001];the BUN level in the observation group is lower than that of the control group[MD=-1.38,95%CI(-2.06,-0.69),P<0.00001]:the HbA1C level of the observation group is lower than that of the control group[MD=-0.63,95%CI(-1.14,-0.13),P<0.00001].The results of l7 randomized controlled trials showed a significant reduction in urinary micro-protein excretion rate(UAER)before and after treatment for diabetic nephropathy(P<0.0001).17 randomized controlled trials showed a significant reduction in urinary micro-protein excretion rate(UAER)before and after treatment for diabetic nephropathy(P<0.0001).Con-clusion The existing clinical evidence shows that Jinshuibao combined with western medicine in the treatment of early diabetic nephropathy is more effective than that of simple western medi-cine,which is worthy of clinical promotion and application,but more multi-center large sample randomized controlled trials(RCTs)studies are needed for verification.

Jinshuibaoearly diabetic nephropathyrandomized controlled trial

吕溪涓、李瑜璠、汪四海、方朝晖

展开 >

安徽中医药大学(安徽 合肥 230038)

安徽中医药大学第一附属医院(安徽 合肥 230031)

新安医学教育部重点实验室(安徽中医药大学)(安徽 合肥 230031)

金水宝 早期糖尿病肾病 随机对照试验

国家自然科学基金安徽省高校协同创新项目

81774286GXXT-2020-025

2024

湖北民族大学学报(医学版)

湖北民族大学学报(医学版)

ISSN:
年,卷(期):2024.41(1)
  • 30